ArticleBMC endocrine disorders2025
Predictive diagnostic models for newly diagnosed diabetes mellitus in moderate to severe COVID-19: the role of TyG Index, BMI, and inflammatory markers.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acute Hyperglycaemia, Insulin Resistance, and Cytokine Dysregulation as Predictors of Disease Severity in Non-Diabetic Hospitalised COVID-19 Patients.International journal of molecular sciences · 2026Article
- The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe association between COVID-19 and newly diagnosed diabetes mellitus (DM) remains uncertain. This cross-sectional study examines the role of insulin resistance (IR) and selected inflammatory markers in COVID-19 associated newly diagnosed DM. RESEARCH DESIGN AND
methodsA cross-sectional pilot study was conducted at an academic tertiary hospital and a primary healthcare facility, with COVID-19 patients additionally followed for three months post-discharge. Participants included patients hospitalised with moderate to severe COVID-19 during the third wave of predominantly the delta variant. Diagnostic markers predictive of newly diagnosed DM were assessed using logistic regression analysis. Four predictive diagnostic models were developed, incorporating combinations of triglyceride-glucose index (TyG index), homeostatic model assessment of insulin resistance (HOMA-IR), body mass index (BMI) and inflammatory cytokines. Model performance and optimal cutoff values were determined using Receiver Operating Characteristic (ROC) analysis and the Youden index.
resultsA total of 127 individuals were evaluated, consisting of 84 patients admitted with moderate to severe COVID-19 and 43 healthy controls. Among the 84 COVID-19 participants, 45 were newly diagnosed with DM, 20 had no DM, and 19 had pre-existing DM. Those with newly diagnosed DM exhibited significantly higher BMI and IR markers (HOMA-IR, and TyG index) compared to those without newly diagnosed DM (p < 0.001, p = 0.05 and p = 0.002, respectively). The predictive diagnostic model for newly diagnosed DM included the TyG index, BMI, IL-10 and IL-1β, achieving an area under the curve (AUC) of 0.91 (95% CI, 0.84-0.98). The TyG index was strongly associated with newly diagnosed DM (Crude Odds Ratio [COR] 11.25 (95% CI, 2.80-76.28; p-value = 0.01); Adjusted Odds Ratio (AOR) 6.83 (95% CI, 1.57, 42.96; p-value = 0.01) and showed improved predictive accuracy when used with BMI (AUC 0.86; 95% CI, 0.77-0.95), compared to the TyG index alone (AUC 0.73; 95% CI, 0.59-0.86). These findings support the potential role of the TyG index as a practical alternative to HOMA-IR in resource-limited settings where insulin measurement may not be feasible.
conclusionsIn our study population, IR rather than insulin deficiency was more strongly associated with newly diagnosed DM in patients with COVID-19. The TyG index may serve as a practical diagnostic marker for predicting newly diagnosed DM in resource-limited settings, with BMI and inflammatory markers further improving model accuracy. However, given our predominantly Black African study population, validation in larger and more diverse populations is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.